Add to ORKGIntroduction: Chemotherapy resistance is responsible for high mortality rates in high-risk neuroblastoma patients. MYCN is a major oncogenic driver in these tumors controlling pluripotency genes including LIN28B. Therefore, we hypothesized that enhanced embryonic stem cell (ESC) gene regulatory programs could mark tumors with increased risk for therapy failure enabling the selection of patients for novel targeted therapies. M&M: A microRNA expression ESC-signature was established based on publically available data. In addition, an mRNA ESC-signature of top 500 protein coding genes with highest positive correlation with the microRNA ESC-signature score was generated. Results: High ESC-signature scores were significantly correlated with wor...
Neuroblastoma is a childhood cancer derived from embryonic neural crest cells of the peripheral symp...
Neuroblastoma (NB) is a malignant tumor that accounts for ~15% of all pediatric cancer mortality. Ne...
Despite intensive study, many mysteries remain about the MYCN oncogene\u27s functions. Here we focus...
Introduction: Chemotherapy resistance is responsible for high mortality rates in high-risk neuroblas...
Chemotherapy resistance is responsible for high mortality rates in neuroblastoma. MYCN, an oncogenic...
Introduction: The past decade several high throughput technologies have been developed that allow to...
Nearly half of patients with neuroblastoma present with high-risk disease, which often has poor outc...
Background: Neuroblastic tumors are often addicted to the MYCN protooncogene. Results: Using a genom...
Neuroblastoma is a highly heterogenous cancer of childhood. High-risk disease has a poor prognosis w...
Neuroblastoma is the first neurogenic-extracranial solid cancer occurring in infancy and childhood. ...
High-risk neuroblastoma has an overall survival of only 50%, and alternative treatment options for t...
Neuroblastoma is an embryonal malignancy that accounts for 15 % of all cancer related deaths amongst...
MYCN, an oncogenic transcription factor of the Myc family, is a major driver of neuroblastoma tumori...
Background. Neuroblastoma is the most common pediatric solid extracranial malignancy. Increased expr...
Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge ...
Neuroblastoma is a childhood cancer derived from embryonic neural crest cells of the peripheral symp...
Neuroblastoma (NB) is a malignant tumor that accounts for ~15% of all pediatric cancer mortality. Ne...
Despite intensive study, many mysteries remain about the MYCN oncogene\u27s functions. Here we focus...
Introduction: Chemotherapy resistance is responsible for high mortality rates in high-risk neuroblas...
Chemotherapy resistance is responsible for high mortality rates in neuroblastoma. MYCN, an oncogenic...
Introduction: The past decade several high throughput technologies have been developed that allow to...
Nearly half of patients with neuroblastoma present with high-risk disease, which often has poor outc...
Background: Neuroblastic tumors are often addicted to the MYCN protooncogene. Results: Using a genom...
Neuroblastoma is a highly heterogenous cancer of childhood. High-risk disease has a poor prognosis w...
Neuroblastoma is the first neurogenic-extracranial solid cancer occurring in infancy and childhood. ...
High-risk neuroblastoma has an overall survival of only 50%, and alternative treatment options for t...
Neuroblastoma is an embryonal malignancy that accounts for 15 % of all cancer related deaths amongst...
MYCN, an oncogenic transcription factor of the Myc family, is a major driver of neuroblastoma tumori...
Background. Neuroblastoma is the most common pediatric solid extracranial malignancy. Increased expr...
Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge ...
Neuroblastoma is a childhood cancer derived from embryonic neural crest cells of the peripheral symp...
Neuroblastoma (NB) is a malignant tumor that accounts for ~15% of all pediatric cancer mortality. Ne...
Despite intensive study, many mysteries remain about the MYCN oncogene\u27s functions. Here we focus...